Hemophilia diagnosis - Hemophilia News Today
Oct 20, 2023 · Hemophilia is caused by the lack of clotting factors, that is, specific proteins needed for blood to clot. Each type of hemophilia is marked by a deficiency of a different clotting factor — factor VIII (FVIII) in hemophilia A, factor IX (FIX) in hemophilia B, and factor XI (FXI) in hemophilia C.In most patients, low clotting factor levels …
Giroctocogene fitelparvovec for hemophilia
Jan 11, 2024 · Giroctocogene fitelparvovec, formerly known as SB-525 or PF-07055480, is a gene therapy being developed to reduce the risk of bleeding episodes in people with hemophilia A. Given as a single intravenous or into-the-vein infusion, the medication is designed to provide a functioning copy of the F8 gene, which is mutated in hemophilia A patients ...
Hemophilia symptoms: Early signs and complications - Hemophilia …
Oct 18, 2023 · Hemophilia is a rare disorder in which the blood doesn’t clot properly, resulting in the disease’s hallmark symptoms of bleeds — excessive bleeding that extends over a prolonged period of time — that in turn leads to other complications. Bleeds can occur outside the body (external bleeding) or within the body (internal bleeding). In …
Hemophilia A vs. B: Differences and similarities - Hemophilia News …
Dec 1, 2023 · Hemophilia A is more common. It accounts for approximately 80% of all hemophilia cases. Hemophilia B is the second most prevalent type of the bleeding disorder, making up the remaining 15% to 20% of cases.. Though they have different causes, hemophilia types A and B do also share similarities, with both occurring primarily in …
Approved Treatments for Hemophilia – Hemophilia News Today
Sevenfact. Sevenfact (eptacog beta) is a bypassing agent that’s approved to treat bleeding episodes in people with hemophilia A or hemophilia B who developed inhibitors, or neutralizing antibodies, against clotting factor VIII or factor IX. It’s indicated for …
FEIBA (factor eight inhibitor bypassing activity) for hemophilia
Nov 9, 2023 · FEIBA (factor eight inhibitor bypassing activity), also known as activated prothrombin complex concentrate and anti-inhibitor coagulant complex, is a bypassing agent that’s approved to prevent or control bleeding episodes in people with hemophilia A and hemophilia B. It can be prescribed for patients with inhibitors, or neutralizing ...
Eloctate (efmoroctocog alfa) for hemophilia - Hemophilia News …
Dec 4, 2023 · Eloctate (efmoroctocog alfa) is an extended half-life therapy that’s approved to prevent and treat bleeds, including those occurring during surgery, in adults and children with hemophilia A. Its design allows it to last for a longer time in the body, thus requiring fewer doses. The therapy, which is administered via an intravenous or into-the ...
Altuviiio (efanesoctocog alfa) for hemophilia
Aug 22, 2024 · Altuviiio (efanesoctocog alfa) is an approved long-lasting factor VIII (FVIII) replacement therapy used to reduce the frequency of bleeding episodes or control and manage active bleeds, including those occurring during surgery, in children and adults with hemophilia A. Previously known as BIVV001, it’s administered via an into-the-vein ...
Antifibrinolytics - Hemophilia News Today
Antifibrinolytics are medicines that promote blood clotting by preventing or slowing down a process called fibrinolysis, which is the break down of blood clots.Antifibrinolytics are used as a treatment for hemophilia, in surgical procedures to prevent excessive blood loss, and for heavy menstrual bleeding.. How antifibrinolytics work. Hemostasis is a …
Roctavian (formerly Valrox/BMN 270) - Hemophilia News Today
Sep 15, 2023 · Roctavian is a one-time gene therapy that uses a modified and harmless adeno-associated virus, called AAV5, to carry and deliver a shorter, but functional, version of the F8 gene to cells in the liver, the main producer of clotting factors. The therapy, formerly known as Valrox or BMN 270, is expected to restore FVIII levels, thereby lowering ...